Dec 01, 2022 / 02:40PM GMT
Josh Schimmer - Evercore ISI - Analyst
This is Josh Schimmer from the Evercore ISI Biotech team. Very pleased to introduce. From Atreca, we have John Orwin, President and Chief Executive Officer; Steven Gould, Chief Scientific Officer; Herb Cross, Chief Financial Officer; Tito Serafini, Chief Strategy Officer; and we also have Alex Gray from Corporate Communications with us.
So gentlemen, welcome. Thanks so much for joining. Why don't we just kind of start with a snapshot of Atreca's platform and where you are in that division kind of company.
John Orwin - Atreca, Inc. - President and CEO
Sure. And I'll take that one unless you want to dive deeper into the platform. But essentially, we have a validated platform that allows us to discover novel antibody target pairs by interrogating the human immune response platform involves high-throughput sequencing of B cell plasmablasts of our serial samples so that we can look at the emergence or expansion or persistence of different B cell clones that help us to identify antibodies that may be important in the
Atreca Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers